📊 VCYT Key Takeaways
Is Veracyte, Inc.. (VCYT) a Good Investment?
Veracyte demonstrates exceptional financial health with zero debt, $362.6M cash reserves, and strong free cash flow generation ($126.6M, 24.5% margin) supporting a high-quality medical lab business model (70% gross margin). However, net income stagnation despite 16% revenue growth and depressed returns on equity (5.1%) signal operational deleverage and inefficient capital deployment, warranting cautious positioning.
Why Buy Veracyte, Inc.. Stock? VCYT Key Strengths
- Financial fortress: zero debt, 8.15x current ratio, $362.6M cash provides substantial strategic flexibility
- Exceptional cash generation: $126.6M free cash flow (24.5% FCF margin) with FCF exceeding net income, indicating high-quality earnings
- Strong revenue growth and market positioning: 16% YoY revenue growth with 70.1% gross margins typical of premium diagnostic services
VCYT Stock Risks: Veracyte, Inc.. Investment Risks
- Operating deleverage: net income flat YoY despite 16% revenue growth indicates margin compression or expense growth outpacing revenue
- Poor capital efficiency: ROE of 5.1% and ROA of 4.7% suggest the company is not adequately deploying its $1.4B asset base
- Insider activity spike: 22 Form 4 filings in 90 days warrants monitoring for executive transactions or potential strategic changes
Key Metrics to Watch
- Operating margin expansion and operating leverage as revenue scales
- Return on equity trajectory and cash deployment strategy (acquisitions, buybacks, or dividends)
- Net income growth resumption and drivers of flat profitability despite strong top-line growth
Veracyte, Inc.. (VCYT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 24.5% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 8.15x current ratio provides a solid financial cushion.
VCYT Profit Margin, ROE & Profitability Analysis
VCYT vs Healthcare Sector: How Veracyte, Inc.. Compares
How Veracyte, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Veracyte, Inc.. Stock Overvalued? VCYT Valuation Analysis 2026
Based on fundamental analysis, Veracyte, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Veracyte, Inc.. Balance Sheet: VCYT Debt, Cash & Liquidity
VCYT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Veracyte, Inc..'s revenue has grown significantly by 136% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.02 indicates the company is currently unprofitable.
VCYT Revenue Growth, EPS Growth & YoY Performance
VCYT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $115.9M | $15.2M | $0.19 |
| Q2 2025 | $114.4M | -$980.0K | $-0.01 |
| Q1 2025 | $96.8M | -$1.9M | $-0.02 |
| Q3 2024 | $90.1M | $15.2M | $0.19 |
| Q2 2024 | $90.3M | $3.9M | $0.05 |
| Q1 2024 | $82.4M | -$1.9M | $-0.02 |
| Q3 2023 | $75.6M | -$8.7M | $-0.12 |
| Q1 2023 | $67.8M | -$8.1M | $-0.11 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Veracyte, Inc.. Dividends, Buybacks & Capital Allocation
VCYT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Veracyte, Inc.. (CIK: 0001384101)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VCYT
What is the AI rating for VCYT?
Veracyte, Inc.. (VCYT) has an AI rating of HOLD with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VCYT's key strengths?
Claude: Financial fortress: zero debt, 8.15x current ratio, $362.6M cash provides substantial strategic flexibility. Exceptional cash generation: $126.6M free cash flow (24.5% FCF margin) with FCF exceeding net income, indicating high-quality earnings.
What are the risks of investing in VCYT?
Claude: Operating deleverage: net income flat YoY despite 16% revenue growth indicates margin compression or expense growth outpacing revenue. Poor capital efficiency: ROE of 5.1% and ROA of 4.7% suggest the company is not adequately deploying its $1.4B asset base.
What is VCYT's revenue and growth?
Veracyte, Inc.. reported revenue of $517.1M.
Does VCYT pay dividends?
Veracyte, Inc.. does not currently pay dividends.
Where can I find VCYT SEC filings?
Official SEC filings for Veracyte, Inc.. (CIK: 0001384101) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VCYT's EPS?
Veracyte, Inc.. has a diluted EPS of $0.82.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VCYT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Veracyte, Inc.. has a HOLD rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VCYT stock overvalued or undervalued?
Valuation metrics for VCYT: ROE of 5.1% (sector avg: 15%), net margin of 12.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VCYT stock in 2026?
Our dual AI analysis gives Veracyte, Inc.. a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is VCYT's free cash flow?
Veracyte, Inc..'s operating cash flow is $136.3M, with capital expenditures of $9.7M. FCF margin is 24.5%.
How does VCYT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 12.8% (avg: 12%), ROE 5.1% (avg: 15%), current ratio 8.15 (avg: 2).